Volux xc

Get Ready to Snatch that Jawline!
Coming Early 2023

Allergan Aesthetics, an AbbVie company, has announced the US Food and Drug Administration (FDA) has approved JUVÉDERM VOLUX XC (hyaluronic acid filler) for the improvement in jawline definition in patients 21 years and older with moderate to severe loss of jawline definition.

"The approval of JUVÉDERM VOLUX XC represents the largest leap in innovation for our U.S. HA portfolio since the introduction of JUVÉDERM VOLUMA XC," said Carrie Strom, president of Global Allergan Aesthetics and senior vice president of AbbVie. "JUVÉDERM VOLUX XC complements our existing product line to provide even more structure, cohesivity, and lift capacity to create an improved jawline that appears more defined in real life and on camera. JUVÉDERM VOLUX XC is what our providers have been asking for to deliver the jaw-dropping results their patients are seeking."

 

What else should you know about JUVÉDERM VOLUX XC?

  • First and only Hyaluronic Acid (HA) filler FDA-approved to improve jawline definition

  • Clinically proven to last up to 1 year with optimal treatment.

  • JUVÉDERM VOLUX XC is from the makers of the #1 family of fillers.

  • After 24 hours, you should be able to resume your normal activities.

  • Side effects are moderate and generally last 2 to 4 weeks. Common side effects include temporary reactions at the treatment site such as tenderness, swelling, firmness, lumps/bumps, bruising, pain, redness, discoloration, and itching.

PicMonkey-cropped2-1024x512.jpg

JAW
DEFINITION

As we age, the lower portion of our face tends to suffer from volume loss, and in turn, creates the appearance of jowls. VOLUX is here to help restore that loss and create a more defined jaw! 

download.jpg

Ready To Set Up A Complimentary Consultation?

Book online or

Call/Text Us

610.349.6390